Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma

BMC Medical Genomics

Table 1 Clinical features of DLBCL patients at the time of diagnosis (n = 74)

	All group (n = 74)	TP53mut (n = 12)	TP53wt (n = 62)	P-value (TP53mut vs. TP53wt)
Mean age (yrs)	52.8 ± 14.3	50.3 ± 10.6	58.6 ± 18.5	0.347
Sex				0.403
M	35	7	28
F	39	5	34
B-symptoms				0.016
No	36	2	34
Yes	38	10	28
Performance score				0.352
0 + 1	57	8	49
2–3	17	4	13
Stage				0.264
I-II	7	0	7
III-IV	67	12	55
Extranodal foci				0.074
No	42	4	38
Yes	32	8	24
Splenomegaly				0.044
No	59	7	52
Yes	15	5	10
Bone marrow involvement				0.028
No	51	4	47
Yes	23	8	15
S-LDH				0.296
Normal	41	5	36
Elevated	33	7	26
IPI score				0.018
0–2	21	0	21
3–5	53	12	41
Therapy response
CR	58	7	51	0.066

Abbreviations: M male, F female, S-LDH serum lactate dehydrogenase, IPI International Prognostic Index, CR complete remission

ISSN: 1755-8794